No. 371 Lishizhen Road
In 2004, Roche set up a research and early development center (Roche R&D Center (China) Ltd.) in Shanghai. It is the first fully owned multinational pharmaceutical R&D center in Shanghai, now known as the Roche Innovation Center Shanghai (RICS). In 2019, a world class new RICS lab building with a total space of 26,000 square meters was completed after an investment of 863 million CNY. With the establishment of the new lab building, Roche has invested a full value chain in the campus located in Zhangjiang Hi-Tech Park in Shanghai – from Discovery, Development and Manufacturing to Sales and Marketing. The aspiration of Roche is to build a campus that becomes the third strategic center following the world headquarters in Basel, and the US headquarters in San Francisco.
As of the end of December 2020, based on the inventions of RICS, 271 patent applications have been filed and 144 have been granted in China, US, EU, or Japan. Nine molecules with contributions from the site have already entered clinical development. Meanwhile, RICS collaborates with many renowned external academic institutes, biotech companies and contract research organizations within and outside of China to drive the drug discovery and translational medicine activities in China.
Currently RICS has about 200 scientists covering all positions in the functions of pharmaceutical discovery and early development. In addition, about 95% of our staff are Chinese. As a global base for anti-HBV drug discovery and development, RICS has participated in the research and clinical development of four anti-HBV molecules, which are currently being developed, and has played a leading role in some programs. The site is expanding in the therapeutic area of immunology. It is also establishing capabilities in the therapeutic area of oncology. Further growth in number of employees and expansion of research and development areas are planned for the long term success of the site. This fully reflects Roche's commitment to drug discovery and development in China to benefit patients in China and worldwide.